Advanced search
Publication Cover
Clinical and Experimental Hypertension Volume 33, 2011 - Issue 8
Submit an article Journal homepage
311
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Beneficial Effect of Switching from a Combination of Angiotensin II Receptor Blockers other than Losartan and Thiazides to a Fixed Dose of Losartan/Hydrochlorothiazide on Uric Acid Metabolism in Hypertensive Patients

Katsuhiko OhshiroDepartment of Cardiovascular Medicine, Nephrology and Neurology, School of Medicine, University of the Ryukyus, Nishihara-cho, Okinawa, Japan
,
Atsushi SakimaDepartment of Cardiovascular Medicine, Nephrology and Neurology, School of Medicine, University of the Ryukyus, Nishihara-cho, Okinawa, Japan;Health Administration Center, University of the Ryukyus, Nishihara-cho, Okinawa, JapanCorrespondence[email protected]
,
Seigo NakadaKeiaikai Chibana Clinic, Okinawa City, Okinawa, Japan
,
Kentaro KohaguraDepartment of Cardiovascular Medicine, Nephrology and Neurology, School of Medicine, University of the Ryukyus, Nishihara-cho, Okinawa, Japan
,
Masanobu YamazatoDepartment of Cardiovascular Medicine, Nephrology and Neurology, School of Medicine, University of the Ryukyus, Nishihara-cho, Okinawa, Japan
,
Takeshi TanaShuri Jokamachi Clinic Daiichi, Naha, Japan
&
Yusuke OhyaDepartment of Cardiovascular Medicine, Nephrology and Neurology, School of Medicine, University of the Ryukyus, Nishihara-cho, Okinawa, Japan
 show all
Pages 565-570 | Received 29 Nov 2011, Accepted 02 Feb 2011, Published online: 29 Sep 2011

REFERENCES

  • Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560–2572.
  • Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751–1762.
  • Ogihara T, Kikuchi K, Matsuoka H, et al. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32:3–107.
  • Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217–223.
  • Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10–17.
  • Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ 2003; 326:1427–1434.
  • Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18:1149–1154.
  • Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34:144–150.
  • Høieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65:1041–1049.
  • Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811–1821.
  • Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 23:447–452.
  • Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320:211–217.
  • Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21:1157–1162.
  • Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56:1879–1885.
  • Sakima A, Ohshiro K, Nakada S, et al. Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension. Clin Exp Hypertens 2011; 33:309–315.
  • Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998; 32:917–933.
  • Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982–992.
  • Kita T, Yokota N, Ichiki Y, et al. One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertens Res 2010; 33:320–325.
  • Naritomi K, Fujita T, Ito S, et al. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. Hypertens Res 2008; 31:295–304.
  • Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73:1303–1309.
  • Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417–2428.
  • Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43:4–9.
  • Giacomello A, Di Sciascio N, Quaratino CP. Relation between serum triglyceride level, serum urate concentration, and fractional urate excretion. Metabolism 1997; 46:1085–1089.
  • Lin JL, Tan DT, Ho HH, Yu CC. Environmental lead exposure and urate excretion in the general population. Am J Med 2002; 113:563–568.
  • Uetake D, Ohno I, Ichida K, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010; 49:89–94.
  • Hamada T, Hisatome I, Kinugasa Y, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41:793–797.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.